What is the total financial impact of the China tax audit settlement?

The Company has agreed to an income tax payment of approximately RMB 446 million, which includes surcharges and related interest. Based on a rough conversion rate, this is approximately $63.4 million, though investors should refer to the Company's official financial statements for the exact U.S. dollar equivalent and its impact on the balance sheet.

Will this tax settlement result in any penalties?

No, the settlement with the Chinese tax authority did not involve any administrative penalties. This is a positive aspect of the resolution.

Are there other ongoing tax audits that could impact the company?

Yes, the Company previously disclosed that it is subject to ongoing tax audits in other jurisdictions outside of the United States. These audits may result in liabilities that could be materially different from current estimates due to the complex nature of local tax regulations.

ONC/BEIGF 8-K SEC Disclosure

Q: When will this payment affect BeOne Medicines' financial statements?

The income tax payment is expected to be recognized in the Company's U.S. GAAP financial statements for the second quarter of fiscal year 2026.

Summary

BeOne Medicines Ltd. (ONC) announced the conclusion of a statutory tax audit in China. Through a settlement with the local tax authority, the Company has agreed to an income tax payment of approximately RMB 446 million, which includes surcharges and related interest. Importantly, this settlement did not involve any administrative penalties. This payment is anticipated to be recognized in the Company's U.S. GAAP financial statements for the second quarter of fiscal year 2026. This event is a follow-up to previously disclosed ongoing tax audits in various international jurisdictions, which carry the risk of materially different liabilities than currently estimated.

Key Highlights

1Conclusion of a statutory tax audit in China.
2Agreed settlement with Chinese tax authorities for RMB 446 million (approximately $63.4 million based on current exchange rates).
3The settlement includes income tax, surcharges, and related interest.
4No administrative penalties were imposed as part of the settlement.
5The financial impact is expected to be recognized in the Q2 2026 U.S. GAAP financial statements.
6This event relates to ongoing tax audits in various international jurisdictions, highlighting potential for future financial adjustments.

BeOne Medicines Ltd. 8-K Report, Corporate Update (Jun 26, 2026)

Summary

Key Highlights

Frequently Asked Questions